CORD-19:038354e8830fe01feb621a12e8a8c467a15b6354 / 151788-151988 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T947","span":{"begin":0,"end":200},"obj":"Sentence"},{"id":"T16681","span":{"begin":0,"end":200},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Phase I trials demonstrated that ruprintrivir had minimal treatment-related adverse nasal effects and that there were high nasal mucus concentrations of ruprintrivir 12 h after intranasal inoculation."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T15","span":{"begin":0,"end":200},"obj":"Sentence"}],"text":"Phase I trials demonstrated that ruprintrivir had minimal treatment-related adverse nasal effects and that there were high nasal mucus concentrations of ruprintrivir 12 h after intranasal inoculation."}

{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T136","span":{"begin":123,"end":134},"obj":"Body_part"},{"id":"T137","span":{"begin":129,"end":134},"obj":"Body_part"}],"attributes":[{"id":"A136","pred":"uberon_id","subj":"T136","obj":"http://purl.obolibrary.org/obo/UBERON_0002306"},{"id":"A137","pred":"uberon_id","subj":"T137","obj":"http://purl.obolibrary.org/obo/UBERON_0000912"}],"text":"Phase I trials demonstrated that ruprintrivir had minimal treatment-related adverse nasal effects and that there were high nasal mucus concentrations of ruprintrivir 12 h after intranasal inoculation."}